GHSI Guardion Health Total Debt to Capital

Corporate emblem and logo of Guardion Health Science (GHSI)

The success of Guardion Health Science (GHSI) relies on physician trust and the availability of medications in pharmacies. Its narrow specialization in ophthalmic supplements is currently being adjusted through the sale of non-core assets. The confirmed price history on the GURU.Markets platform chart shows that the debt-to-equity ratio is 0.00. Looking ahead, Guardion Health Science (GHSI) plans to expand B2B sales to secure a dominant position in the specialized vision nutraceuticals segment.

GHSI: Guardion Health Sciences Total Debt to Capital 07/04/2022 - 10/19/2024

Analytical breakdowns and data insights for company Guardion Health (GHSI)

- price and consensus price forecast:
Price Chart Guardion Health Sciences|GHSI - Forecast Levels Chart
- market capitalization data:
Market Capitalization Guardion Health Sciences|GHSI - Value Adjusted for Debt and Cash
- book capitalization data:
Book Value per Share Guardion Health Sciences|GHSI - Book Capitalization|Market Value to Book Value Ratio guardionhealth.com|GHSI - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Guardion Health Science|GHSI - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Guardion Health Science|GHSI - Company Aggregate Debts|Debt to Book Value Guardion Health Sciences
Comprehensive company analysis:GHSI - Guardion Health Sciences
Brand item of Guardion Health

Guardion Health Science specializes in niche nutraceuticals for the treatment of glaucoma, leveraging expert ophthalmologist recommendations to bypass mass-market competition. The total liabilities-to-equity ratio determines the business's financial autonomy, allowing investors to assess bankruptcy risk and the efficiency of leverage management through changes in the proportion of debt to equity.

Main competitors

Debt to Equity Alcon ALC|Aggregate Debt to Equity Bausch & Lomb|Glaukos Corp. (GKOS) - Total Debt to Capital|All Debt to Shareholders' Equity Ratio Apellis Corp (APLS)|Total Debt to Capital BLTE (Belite Bio Corp)|ocutx.com - Total Debt to Capital|Debt to Equity Harrow (HROW)|VRDN: All Debt to Shareholders' Equity Ratio|LENZ (LENZ Pharma) - Debt to Equity|Oculis Holding AG (OCS) - Total Debt to Equity Ratio|EYPT (EyePoint Pharmaceuticals) - Total Debt to Capital|Total Debt to Capital kodiak.com (KOD)|Aldeyra Therapeutics (ALDX) - Total Debt to Equity Ratio|All Debt to Shareholders' Equity Ratio kalarx.com (KALA)|IRD: Total Debt to Capital|OKYO - Debt to Capital|ADVM (Adverum) - Total Debt to Equity Ratio|OTLK - Debt to Capital|Total Debt to Capital CLSD|NBY (NovaBay Pharmaceuticals, Inc.) - Debt to Capital|KPRX: Debt to Equity|Total Debt to Capital Coefficient Alimera|EYEN: Total Debt to Capital|Debt to Capital Ratio ocuphire.com OCUP|Total Debt to Equity Ratio OPT (Opthea)